The analysis of delta9-tetrahydrocannabinol and metabolite in whole blood and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in urine using disposable pipette extraction with confirmation and quantification by gas chromatography-mass spectrometry.

Essential to forensic laboratories is the desire to find a more sensitive, rapid method of analyzing Delta9-tetrahydrocannabinol (THC) and metabolite in biological specimens. Disposable pipette extraction (DPX) is a valuable method in extracting THC and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid (THCc) in blood and THCc in urine. Less waste and solvent usage; smaller specimen volume; clean chromatograms; and utilization of lowcost equipment and consumables were achieved using this method.

Sensory correlations in autism.

This study examined the relationship between auditory, visual, touch, and oral sensory dysfunction in autism and their relationship to multisensory dysfunction and severity of autism. The Sensory Profile was completed on 104 persons with a diagnosis of autism, 3 to 56 years of age. Analysis showed a significant correlation between the different processing modalities using total scores.

The pattern of sensory processing abnormalities in autism.

The study was undertaken to evaluate the nature of sensory dysfunction in persons with autism. The cross-sectional study examined auditory, visual, oral, and touch sensory processing, as measured by the Sensory Profile, in 104 persons with a diagnosis of autism, 3-56 years of age, gender-and age-matched to community controls. Persons with autism had abnormal auditory, visual, touch, and oral sensory processing that was significantly different from controls.

Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study.

Background: Imiquimod is currently approved for the treatment of genital warts and has been shown to decrease recurrences of genital herpes in the guinea pig model of genital herpes. Therefore, we evaluated the safety and potential of topical imiquimod to decrease the rate of recurrence in humans with a history of recurrent herpes labialis.

Methods: Forty-seven subjects with recurrent herpes labialis applied imiquimod 5% (n=30) or vehicle cream (n=17) to recurrent lesion(s) on days 1, 3, and 5 of the study (day 1 of observation occurred within 48 h after recurrence of lesion).